CHEN Naihong
Principal Investigator
Professor Chen is mainly engaged in the research of neuropsychopharmacology, neurologic molecular biology, pharmacology of traditional Chinese medicine, novel drug development and mechanism research for nervous system diseases and inflammatory diseases. In recent years, Chen and his team have chaired or participated in more than 40 projects in the national or provincial level including major projects and general projects. Professor Chen has published more than 300 research papers including more than 160 SCI papers and hosted or participated in the preparation of 18 academic monographs. He has been granted 8 patents and awarded the second prize of Chinese Medical Science for 2010 and 2012, the second prize of Beijing Science and Technology for 2011 and the third prize of Beijing Science and Technology for 2012.
1. The Therapeutic Role of Cannabinoid Receptors and Its Agonists or Antagonists in Parkinson's Disease. Prog Neuropsychopharmacol Biol Psychiatry. 2020;96:109745.
2. CZ-7, a New Derivative of Claulansine F, Promotes Remyelination Induced by Cuprizone by Enhancing Myelin Debris Clearance. Brain Res Bull. 2020;159:67-78.
3. Potential Application of Endocannabinoid System Agents in Neuropsychiatric and Neurodegenerative Diseases-Focusing on FAAH/MAGL Inhibitors. Acta Pharmacol Sin. 2020;41(10):1263-1271.
4. Donepezil Attenuates Vascular Dementia in Rats Through Increasing BDNF Induced by Reducing HDAC6 Nuclear Translocation. Acta Pharmacol Sin. 2020;41(5):588-598.
5. Anti-inflammatory effects of higenamine (Hig) on LPS-activated mouse microglia (BV2) through NF-κB and Nrf2/HO-1 signaling pathways. Int Immunopharmacol. 2020;85:106629.
6. Nurr1: A vital participant in the TLR4-NF-κB signal pathway stimulated by α-synuclein in BV-2 cells. Neuropharmacology. 2019;144:388-399.
7. Ginsenoside Rg1 protects against ischemic/reperfusion-induced neuronal injury through miR-144/Nrf2/ARE pathway. Acta Pharmacol Sin. 2019;40(1):13-25.
8. IMM-H004 protects against oxygen-glucose deprivation/reperfusion injury to BV2 microglia partly by modulating CKLF1 involved in microglia polarization. Int Immunopharmacol. 2019;70:69-79.
9. RNAi-mediated knockdown of DJ-1 leads to mitochondrial dysfunction via Akt/GSK-3ß and JNK signaling pathways in dopaminergic neuron-like cells. Brain Res Bull. 2019;146:228-236.
10. The effects of glucocorticoids on depressive and anxiety-like behaviors, mineralocorticoid receptor-dependent cell proliferation regulates anxiety-like behaviors. Behav Brain Res. 2019;362:288-298.
11. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease. Int Immunopharmacol. 2019;67:458-464.
12. CZ-7, a new derivative of Claulansine F, ameliorates 2VO-induced vascular dementia in rats through a Nrf2-mediated antioxidant responses. Acta Pharmacol Sin. 2019;40(4):425-440.
13. IMM-H004 Protects against Cerebral Ischemia Injury and Cardiopulmonary Complications via CKLF1 Mediated Inflammation Pathway in Adult and Aged Rats. Int. J. Mol. Sci. 2019, 20, 1661.
14. A20 as a novel target for the anti-neuroinflammatory effect of chrysin via inhibition of NF-κB signaling pathway. Brain Behav Immun. 2019; 79:228-235.
15. CKLF1 Aggravates Focal Cerebral Ischemia Injury at Early Stage Partly by Modulating Microglia/Macrophage Toward M1 Polarization Through CCR4. Cell Mol Neurobiol. 2019;39(5):651-669.
16. NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP. Acta Pharmacol Sin. 2019;40(8):991-998.
17. IMM-H004 therapy for permanent focal ischemic cerebral injury via CKLF1/CCR4-mediated NLRP3 inflammasome activation. Transl Res. 2019;212:36-53.
18. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson's disease. Acta Pharmacol Sin. 2019;40(12):1503-1512.
19. Chemokines play complex roles in cerebral ischemia. Neurochem Int. 2018;112:146-158.
20. Gap junction channels as potential targets for the treatment of major depressive disorder. Psychopharmacology (Berl). 2018;235(1):1-12.
21. RTP801 is a critical factor in the neurodegeneration process of A53T alpha-synuclein in a mouse model of Parkinson's disease under chronic restraint stress. Br J Pharmacol. 2018 Feb;175(4):590-605.
22. NLRP3 inflammasome activation in the thymus of MPTP-induced Parkinsonian mouse model. Toxicol Lett. 2018 May 15;288:1-8.
23. A novel mechanism of depression: role for connexins. Eur Neuropsychopharmacol. 2018 Apr;28(4):483-498.
24. Anti-neuroinflammatory effects of 20C from Gastrodia elata via regulating autophagy in LPS-activated BV-2 cells through MAPKs and TLR4/Akt/mTOR signaling pathways. Mol Immunol. 2018 Jul;99:115-123.
25. Prion-like propagation of α-synuclein in the gut-brain axis. Brain Res Bull. 2018 Jun;140:341-346.
26. Glucocorticoid receptor activation induces decrease of hippocampal astrocyte number in rats. Psychopharmacology (Berl). 2018 Sep;235(9):2529-2540.
27. Ursodeoxycholic acid protects interstitial Cajal-like cells in the gallbladder from undergoing apoptosis by inhibiting TNF-α expression. Acta Pharmacol Sin. 2018 Sep;39(9):1493-1500.
28. The extended application of the rat brain in stereotaxic coordinates in rats of various body weight. J Neurosci Methods. 2018 Sep 1;307:60-69.
29. IMM-H004, a Novel Coumarin Derivative Compound, Inhibits H2O2-Induced Neurotoxicity via Antioxidant and Antiapoptosis in PC12 Cells. J Stroke Cerebrovasc Dis. 2018 Dec;27(12):3396-3403.
30. Corticosterone impairs gap junctions in the prefrontal cortical and hippocampal astrocytes via different mechanisms. Neuropharmacology. 2018 Mar 15;131:20-30.
31. Progress in Pharmacological Research of chemokine like factor 1 (CKLF1). Cytokine. 2018 Feb;102:41-50.
32. Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease. Acta Pharmacol Sin. 2017 Oct;38(10):1317-1328.
33. Ginsenoside Rg1-induced antidepressant effects involve the protection of astrocyte gap junctions within the prefrontal cortex. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Apr 3;75:183-191.
34. Possible target-related proteins of stress-resistant rats suggested by label-free protemic analysis. RSC Advances 2017; 7: 40957-40964.
35. Upregulating the Expression of Survivin-HBXIP Complex Contributes to the Protective Role of IMM-H004 in Transient Global Cerebral Ischemia/Reperfusion. Mol Neurobiol. 2017 Jan;54(1):524-540.
36. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation. Toxicol Lett. 2017 Jan 4;265:30-37.
37. IMM-H004, a coumarin derivative, attenuated brain ischemia/reperfusion injuries and subsequent inflammation in spontaneously hypertensive rats through inhibition of VCAM-1. RSC Advances 2017; 7: 27480–27495.
38. Ginsenoside Rg1 alleviates corticosterone-induced dysfunction of gap junctions in astrocytes. J Ethnopharmacol. 2017 Aug 17;208:207-213.
39. A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the a-Synuclein–Related Inflammatory Response. J Pharmacol Exp Ther. 2017 Nov;363(2):284-292.
40. Antidepressive effects of ginsenoside Rg1 via regulation of HPA and HPG axis. Biomed Pharmacother. 2017 Aug;92:962-971.
